Levosimendan Does Not Reduce Mortality in Critically Ill Adults With Sepsis and Septic Shock: A Meta-Analysis

0
0
0

Levosimendan Does Not Reduce Mortality in Critically Ill Adults With Sepsis and Septic Shock: A Meta-Analysis

Sepsis and septic shock are leading causes of death worldwide—surpassing even acute myocardial infarction, according to the World Health Organization. For patients with these life-threatening conditions, heart dysfunction is common: nearly one-third of sepsis patients develop problems with how their heart pumps, which can lead to heart failure. Doctors often use drugs called inotropes to boost heart function, but traditional options like dobutamine have downsides, including increased risk of arrhythmias (abnormal heart rhythms) and higher oxygen use by the heart. That’s where levosimendan comes in—a calcium sensitizer that boosts heart contractility (the ability to squeeze blood out) without raising oxygen demand. But does it actually save lives in sepsis and septic shock? A 2019 meta-analysis seeks to answer that question.

What the Study Did

A team of researchers from the Department of Intensive Care Unit at Lanzhou University Second Hospital (China) analyzed 20 randomized controlled trials (RCTs)—the gold standard for medical research—to evaluate levosimendan’s effect on mortality in adult sepsis and septic shock patients. RCTs are reliable because they randomly assign patients to treatment (levosimendan) or control (other inotropes like dobutamine, or placebo) groups, reducing bias.

The researchers searched five major databases (PubMed, Embase, Cochrane Library, Wanfang Data, and CNKI) up to August 2018. They excluded duplicate studies, animal research, non-RCTs, and pediatric trials. In total, 1087 patients were included: 738 in the levosimendan group and 729 in the control group.

The study focused on three key outcomes:

  1. Mortality: The main question—did levosimendan reduce how many patients died?
  2. Cardiac index: A measure of how well the heart pumps blood per unit of body size (higher = better).
  3. Serum lactate: A marker of tissue damage from low oxygen (lower = better).

What the Study Found

The results were mixed:

1. No Mortality Benefit

Levosimendan did not reduce deaths compared to the control group. The relative risk (RR) of mortality was 0.90 (95% confidence interval [CI] 0.79–1.03, P=0.13). This means patients on levosimendan were 10% less likely to die—but the difference was not statistically significant (it could have been due to chance).

2. Improved Cardiac Function and Lower Lactate

Levosimendan did help with secondary outcomes:

  • Cardiac index: Increased by a weighted mean difference (WMD) of 0.51 (95% CI 0.06–0.95, P=0.02). This means levosimendan helped the heart pump more efficiently.
  • Serum lactate: Decreased by WMD -1.04 (95% CI -1.47 to -0.60, P<0.00001). This means levosimendan reduced tissue damage from low oxygen.

Why No Mortality Benefit?

If levosimendan improved heart function and reduced tissue damage, why didn’t it save more lives? Two key factors explain this:

1. Heterogeneous Patient Groups

One large study included in the meta-analysis—Gordon et al. (2016) from the New England Journal of Medicine—enrolled 516 patients (half of the total in the meta-analysis). Only 30% of patients in that study had their heart function assessed. This made the group heterogeneous (mixed): some patients had severe heart dysfunction (who might benefit from inotropes like levosimendan), while others didn’t. This mix blurred the mortality results—you can’t see a clear benefit if only some patients need the drug.

2. Pharmacological Advantages (But No Mortality Impact)

Levosimendan has real perks over traditional inotropes:

  • It works by making cardiac cells more sensitive to calcium, boosting contractility without raising oxygen use—a critical benefit for hearts already stressed by sepsis.
  • It has a long half-life (up to 80 hours): a 24-hour infusion can keep working for a week, helping patients stabilize their blood flow and pressure.

But even with these advantages, the meta-analysis didn’t find fewer deaths.

Limitations of the Study

The research isn’t perfect. Key limitations include:

  • Small sample sizes: Most included RCTs had few patients, and one study contributed half the total—this can skew results.
  • Variable mortality definitions: Studies used different ways to measure death (28-day, 30-day, ICU, or hospital mortality), which can affect outcomes.
  • Mixed control groups: The control group used various drugs (dobutamine, milrinone, or guideline-recommended therapy)—each with different mechanisms—making comparisons tricky.
  • Different cardiac index methods: Cardiac index was measured using Swan-Ganz catheters, ultrasound, or PiCCO (a less invasive device)—these differences can introduce bias.

What This Means for Patients and Doctors

Based on this meta-analysis, levosimendan does not reduce mortality in adult critically ill patients with sepsis and septic shock—even though it helps the heart pump better and lowers lactate.

Doctors should use levosimendan cautiously in these patients. The drug may help with hemodynamic stability (stable blood flow and pressure), but there’s no proof it saves lives. Larger, more homogeneous RCTs—where all patients have their heart function assessed—are needed to see if levosimendan benefits specific subsets of sepsis patients (e.g., those with severe heart dysfunction).

The study, “Levosimendan does not reduce the mortality of critically ill adult patients with sepsis and septic shock: a meta-analysis,” was published in the Chinese Medical Journal in 2019 by Fang Feng, Yu Chen, Min Li, Jiao-Jiao Yuan, Xue-Ni Chang, and Chen-Ming Dong of Lanzhou University Second Hospital.

doi: https://doi.org/10.1097/CM9.0000000000000197

Was this helpful?

0 / 0